Research graph
References from Letter Re: “A stromal–immune computational pathology signature for prognosis and immune checkpoint inhibitor response in localized, locally advanced and metastatic urothelial carcinoma: A multicenter retrospective study”. Local targets link to admitted publications; unresolved targets remain external evidence.
A stromal-immune computational pathology signature for prognosis and immune checkpoint inhibitor response in localized, locally advanced and metastatic urothelial carcinoma: a multicenter retrospective study
10.1016/j.ejca.2026.116979 · 2026 · External reference
Statistical methods for assessing agreement between two methods of clinical measurement
10.1016/s0140-6736(86)90837-8 · 1986 · External reference
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression
10.1038/s43018-021-00232-6 · 2021 · External reference
Germinal center-like tertiary lymphoid structures mark immune responsiveness and enable checkpoint immunotherapy in bladder cancer
10.32604/or.2026.077808 · 2026 · External reference
The tumor immune landscape and architecture of tertiary lymphoid structures in urothelial cancer
2021 · External reference
TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods
10.1136/bmj-2023-078378 · 2024 · External reference
Presence, subtypes, and prognostic significance of tertiary lymphoid structures in urothelial carcinoma of the bladder
10.1093/oncolo/oyad283 · 2024 · External reference
Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens
10.1200/jco.2009.25.4599 · 2010 · External reference
Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer
10.1056/nejmoa2312117 · 2024 · External reference
